Cartalax: Research Profile and Protocol Guide

Overview

Cartalax is a synthetic tripeptide bioregulator (Ala-Glu-Asp) developed as part of Professor Vladimir Khavinson's extensive peptide bioregulation research program at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia. It belongs to a class of short peptides (2-4 amino acids) theorized to interact with DNA at the gene level, modulating the expression of genes specific to cartilage and musculoskeletal tissue. Khavinson's bioregulator peptide research spans over 40 years and has resulted in multiple approved medications in Russia, though none have received Western regulatory approval. Cartalax is specifically studied for its effects on cartilage tissue maintenance, joint health, and musculoskeletal aging. The peptide is part of a larger family of tissue-specific bioregulators including Epithalon (pineal), Pinealon (brain), and others that target specific organ systems.

Mechanism of Action

According to Khavinson's bioregulation theory, short peptides like Cartalax interact with specific DNA sequences through complementary charge-based interactions, modulating gene expression in tissue-specific ways. Cartalax is theorized to upregulate genes involved in chondrocyte proliferation, proteoglycan synthesis, and cartilage matrix maintenance while downregulating genes associated with cartilage degradation and inflammatory joint pathology. Research from the Khavinson group suggests these effects occur at very low concentrations, consistent with a signaling or regulatory role rather than a pharmacological one. The peptide may also influence collagen synthesis and bone mineral density through related gene expression pathways.

Research Applications

Cartilage maintenance and joint health research, osteoarthritis and joint degeneration studies, bone density and musculoskeletal aging, bioregulator peptide mechanism research, longevity and healthy aging protocols

Research Protocols

Safety Profile and Considerations

Short peptide bioregulators are generally considered safe in published Russian clinical research. Cartalax has been used in Russian clinical settings as part of longevity protocols. No significant adverse effects reported in published literature. No Western clinical trials or FDA approval. Limited pharmacokinetic data available outside Russian research.

Storage and Stability

Lyophilized: -20C. Stable at room temperature as capsule formulation. See our storage and handling guide for comprehensive best practices.

Published Research

• Khavinson VK. Peptides and Ageing. Neuroendocrinol Lett. 2002
  PMID: 12011877
• Khavinson VK, et al. Short peptides modulate gene expression. Bull Exp Biol Med. 2008
  PMID: 19110580

Search for additional Cartalax research on PubMed.

Where to Source Cartalax

Peptide purity is critical for research accuracy. We evaluate suppliers against our 100-point methodology.